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Dementia and Parkinson’s disease are incurable neurological conditions. Patients often
experience specific, complex, and varying needs along their disease trajectory. Current
management typically employs amultidisciplinary team approach. Recognition is growing
that this team approach should also address palliative care issues to optimize quality
of life for patient and family caregivers, but it remains unclear how palliative care is
best delivered. To inspire future service development and research, we compare the
trajectories and conceptualization of palliative care between dementia and Parkinson’s
disease. Both Parkinson’s disease and dementia are characterized by a protracted
course, with progressive but fairly insidious development of disability. However, patients
with Parkinson’s disease may experience relatively stable periods initially but with time,
a wide range of debilitating symptoms develops, many of which do not respond well
to treatment. Eventually, dementia develops in most Parkinson patients, while motor
disability develops in many dementia patients. In both diseases, symptoms such as pain,
apathy, sleeping problems, falls, and a high caregiver burden are prevalent. Advance care
planning has benefits in terms of being prepared before the disease progresses into a
stage with communication problems or severe cognitive impairment. However, for both
conditions, the protracted disease trajectories complicate conceptualization of palliative
care through different stages of the disease, with pertinent questions such as when to
offer what interventions pro-actively. Given the similarities and differences, we should
develop palliative approaches that are partially generic and partially disease-specific.
These should be integrated seamlessly with disease-specific care. Substantial research
is already being performed on dementia palliative care. This may also inform the further
development of palliative care for Parkinson’s disease, including an evaluation of palliative
interventions and services.
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INTRODUCTION
Palliative care has been developed to improve quality of life,
mostly for patients with incurable cancer (1, 2). However,
equity of access to palliative care involves access on the same
footing for patients with other incurable diseases. This does not
mean that palliative care is, or should be, the same across these
diseases. On the contrary, to optimally tailor care to individuals,
the contents of palliative care, and how, when and where it is
delivered, can and in fact should differ between diseases.
Along the trajectory of chronic-progressive and incurable
neurological diseases such as dementia or Parkinson’s disease
(PD), various complex needs arise, some of which are disease-
specific. Palliative care promotes quality of life in the face
of any life-threatening, or progressive, incurable illness (3, 4).
To optimize it for individuals, however, a good understanding
of disease-specific aspects of palliative care is helpful, i.e., a
conceptualization of what palliative care entails exactly for a
specific disease.
Epidemiology of Dementia and Parkinson’s
Disease (PD)
Dementia and PD are both diagnosed frequently and increase
mortality (5, 6). Perhaps dementia is perceived more so as a
memory problem and a disease of old age, but the incidence of
dementia and PD in younger age is similar. In the Netherlands,
for dementia, the incidence per 1,000 person-years is 0.4 among
those aged 60–64 (7), and for PD, it is 0.3 (ages 55–65) (8, 9).
Dementia incidence patterns, however, show a much steeper
increase with age; mounting to 27 per 1,000 person-years for
those 85 and over, compared to 4 for PD over 85. In view of
similar mortality (6), therefore, the prevalence of dementia in the
general population is much higher than prevalence of PD (8–11).
However, adjusted for age and other factors, 6-year mortality in
PD is higher than in Alzheimer’s dementia (6). Age adjustment is
relevant also as it shows that comorbid disease may be equally
prevalent for Alzheimer’s–a main type of dementia–and PD
across the same age groups (12).
Comparing Trajectories and
Conceptualization of Palliative Care for
Dementia and PD
The two disease trajectories may overlap partly as dementia
is a frequent manifestation of PD. Mild cognitive impairment
may already present upon diagnosis of PD (13). Importantly,
it is independently associated with lower quality of life (14).
Across studies, typically about a quarter of patients with
PD have dementia (15, 16), but ultimately, most develop
dementia (15–17).
A clear conceptualization of palliative care in chronic-
progressive diseases is important for the development of
healthcare systems that facilitate the integration of a palliative
approach (18). Therefore, in this article we compare the disease
trajectories of dementia and PD in as far as relevant for the
conceptualizations of palliative care. We do not include atypical
Parkinsonian disorders such as multiple system atrophy because
these warrant a special approach with earlier palliative care (19).
We first provide background on where we are by describing how
palliative care for dementia and PD developed.
Palliative Care in Dementia
The first evaluated palliative care program specific to dementia
was described in 1986 (20). The volume of research has grown
exponential after 2000 (21, 22). There are few randomized
controlled trials, and therefore, there is still little evidence
on effectiveness (23, 24). However, many western countries
have funded observational studies resulting in numerous
publications describing patient, family and professional caregiver
needs (25, 26).
Research specific to dementia is important because the course
of the disease is highly variable and uncertain. Because of the
progressive dementia, patients themselves often cannot remain
involved in decision making. Also, health services and changes
such as transfer to a hospice, do not necessarily represent optimal
care for people with dementia (27). Palliative care in dementia
needed a clear conceptualization, and the European Association
for Palliative Care (EAPC) along with experts agreed to a distinct
concept in terms of eleven domains, different from “usual”
palliative care (28).
Palliative Care in Parkinson’s Disease
Palliative care for people with PD and their caregivers has
progressed over the last 10 years but it is still an upcoming
field. Evidence of effects is limited (17, 29, 30) but trials are
underway (31). Qualitative studies on palliative care needs (32–
34) and natural history studies (35–37) have indicated that the
needs of people with advanced PD are complex. Awareness of the
potential benefit of palliative care is growing, but we know little
about useful components (17, 29). To the best of our knowledge,
there is no clear conceptualization of the specifics of palliative
care in PD.
DIFFERENCES AND SIMILARITIES
We highlight key similarities and differences between the
trajectories and perceptions of the disease, and treatment and
care for people with dementia and PD based on recent literature.
The comparator is a population without the disease, sometimes
matched or adjusted for differences such as age or co-morbidities.
The Disease Trajectories
With both diseases, the diagnosis may be delayed due to
gradual onset with a-specific symptoms after which burdensome
symptoms develop, while the disease duration is highly variable
(Table 1, items a and b). Burdensome symptoms that decrease
quality of life often include rather unspecific symptoms such as
pain and depression. Clearly, PD is distinct from dementia as
it is characterized by its motor symptoms, such as bradykinesia,
rigidity, and tremor. Symptomatic treatments are available and
with the right therapeutic approach, the course of PD typically
includes an initially relatively stable phase.
For PD patients, loss of functional ability (item c) occurs with
symptoms that are largely unresponsive to treatment speech
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TABLE 1 | The course of dementia and Parkinson’s disease: items relevant to palliative care.
Course of the disease,
items
Dementia Parkinson’s disease
a. Diagnosis, duration, and
staging
Symptoms may occur long before diagnosis of dementia. Onset is
usually after age 65, but when before, duration is usually longer, and
the number of life years lost is greater (5). Survival of dementia patients
is highly variable between individuals and across studies with median
or mean survival generally being between 3 and 12 years from
diagnosis (5, 38, 39)
About half may die before reaching an advanced stage of dementia
when decision making and ADL functioning are severely impaired (40)
and the large majority does not reach a stage in which they are totally
dependent in ADLs, incontinent, bedridden, and mute (41). Definitions
of severe or advanced dementia generally comprise criteria for
cognition combined with criteria for behavior and function including
ADL (42–44)
Prodromal symptoms, such as depression, constipation and
Rapid Eye Movement (REM) sleep behavior disorder may
occur long before diagnosis (45–47). Progression and survival
in Parkinson’s disease is highly variable, and mean duration of
the disease until death ranges between 7 and 14 years (48).
Patient populations are heterogeneous and complex and
therefore the clinical course is variable (49). Given enough
time, the disease is suggested to progress through five
phases: prodromal, stable, unstable, advanced, and
late-stage disease (50). However, consensus on demarcation
of later stages is lacking (51, 52)
b. Symptoms (physical,
psychological, social, and
spiritual) and caregiver
issues
Pain, agitation and shortness of breath are highly prevalent and
burdensome symptoms, and pain and shortness of breath increase
toward the end of life (44, 53) while agitation and other symptoms such
as apathy may increase during the course of the illness in
community-dwelling people (54), but may stabilize or decrease at the
end of life (in nursing home populations) (44, 53) Agitation and
behavioral symptoms of dementia prevalence rates vary widely but
develop at some point in most people with dementia (55, 56). They add
greatly to caregiver burden (57). In particular depression often
compromises quality of life (58). Regarding spirituality, recent studies
show that people with dementia may understand through
remembrance of early life experiences (59, 60)
Diagnosis is based on motor symptoms; bradykinesia,
tremor, and rigidity (61). Parkinson’s disease affects physical,
emotional and psychosocial aspects of life (62, 63).
Compared to motor symptoms, non-motor symptoms, such
as pain, depression, fatigue, psychotic phenomena are more
important in terms of quality of life (64, 65) and they may be
under recognized (66, 67)
Cognitive deficits in Parkinson’s disease may be present
already at diagnosis and affect quality of life (14). There is
significant impairment in executive functions such as poor
planning and problem solving capacities. Up to a majority
may develop dementia ultimately (15–17)
Caregiver burden increases when patients reach advanced
stages due to increasing disability, and also with the
appearance of symptoms such as hallucinations, depression
and falls (68)
c. Functioning Progressive impairment is related to a decline in cognitive and physical
functioning. There is a continuous decline in functioning, e.g., first
dependency in IADL occurs, followed by ADL dependency (69). There
are also various personality changes with different types of dementia;
for example, apathy more commonly develops with Lewy body
dementia compared with Alzheimer’s disease (70, 71)
The disabling nature of Parkinson’s disease increasingly
hinders daily activities and social participation (72). Disease
progression leads to impairments at different levels of body
functions, limitations in a wide variety of ADL and IADL
functioning and in a severe stage, disability, and social
embarrassment occurs
d. Cause of death Dementia is often not mentioned as a cause of death in death
certificate studies, in particular when patients are younger, have mild
dementia and a non-Alzheimer type of dementia (73). Immediate
causes of death are often pneumonia and cardiovascular problems
(73, 74) also in autopsy studies [e.g., (75, 76)]; more often so
compared to people with no dementia
Parkinson’s disease was not reported as the underlying or
contributory cause of death on more than 53% of death
certificates (77). There is a significant increase in deaths from
pneumonia, dementia and other infections (78, 79)
e. Prediction of mortality Strong predictors of mortality are functioning (ADL dependency),
nutritional status or intake (80) and male gender including in acutely ill
patients (81, 82). Higher age and various co-morbid conditions also
relate to increased mortality. Dementia stage, however, is not a strong
predictor of mortality in nursing home residents with dementia (83, 84)
as a fatal pneumonia or food and fluid intake problem also occur before
the advanced stage. Similarly, a late stage on the Functional
Assessment Staging (FAST) scale has no predictive value (85). Of note,
the available prognostic scores do not identify many at risk of death
within a particular timeframe, although they can identify a reasonably
sizeable group of people at low risk of mortality, within, e.g., 6 months
Strong predictors of death in people with Parkinson’s disease
are age, dementia, pneumonia, infections and falls
(6, 79, 86–89). Other studies also found male gender,
comorbidity, axial features and motor and therapy-related
complications to predict mortality (90, 91). Both motor
complications and non-motor symptoms were associated
with mortality at 4 years in a recent study in patients with
Parkinson’s disease and no dementia (91)
problems, postural imbalance and cognitive deterioration;
(51, 92) or with symptoms that may worsen due to treatment
(psychosis, orthostatic hypotension) (51). Other reasons
for functional deterioration are age-related comorbid
disease (92) and under-treatment of symptoms (93, 94),
which also happen with dementia. With dementia, loss
of motor or functional ability often relates to progressive
cognitive dysfunction.
Defining a severe or advanced stage of the disease (item a)
has been recognized as important for palliative care in case of
dementia (42–44). For PD, the most widely used measure to
define disease stage is the Hoehn and Yahr scale (51, 52, 95).
Frontiers in Neurology | www.frontiersin.org 3 March 2019 | Volume 10 | Article 54
van der Steen et al. Dementia and Parkinson’s Disease
However, it selectively focuses on motor function. A recent
consensus study defined key factors for diagnosing advanced PD
including, for example, ADL impairment, and dementia (96).
The stage of dementia is often being perceived as relevant
for palliative care although there is no consensus how exactly
(28). Also, it is not a particularly strong predictor of mortality
among those with moderate or severe dementia, despite sensitive
measures; this may be related to uncertainty as to in what stage
acute problems such as pneumonia develop or different resilience
among long-term survivors (Table 1, items d and e) (74, 83, 84).
Similarly, a late stage on the Functional Assessment Staging
(FAST) scale has shown no predictive value (85), but practice
lags behind, still promoting it for prognostication in dementia
(97). ADL dependency, on the other hand, is a strong predictor
of mortality in dementia (44, 80, 81). In contrast, it may not
predict mortality in PD well (98). In PD, dementia or cognitive
impairment independently predicts mortality (6, 35, 99).
Pneumonia is a relatively frequent cause of death in dementia
and in PD (74, 78, 81). However, well-known problems in coding
practice include dementia being grossly underreported on the
death certificate (73), also in those with PD (78). Similarly, PD
often goes unreported (79).
The overlap between PD and dementia is significant as up
to a majority of patients with PD eventually develop dementia
(9, 16, 17), due to spreading of Lewy bodies. Because of initial
stability and uncertainty as to whether patients develop severe
cognitive problems or die before, PDmay be perceived as an even
more protracted disease course than the dementias.
Conceptualization of the Diseases, Needs,
and Interventions
Both dementia and PD are incurable and progressive diseases
with often complex problems and needs, for which tailored
interventions are available (Table 2, items a–d). For dementia,
experts agree that “recognizing its eventual terminal nature is
the basis for anticipating future problems and an impetus to
the provision of adequate palliative care” (28). Some advocate
advanced dementia to be a terminal disease to support eligibility
for palliative care. However, as about half of dementia patients
never reach an advanced stage (Table 1); (40), it may be a late
trigger to initiate palliative care. There is no consensus, however,
at which stage palliative care in dementia should start (153, 154).
For PD there are no curative treatments either, but the success
of dopaminergic replacement therapy and deep brain stimulation
has enabled the majority of patients to live independently
with a relatively low symptom burden for the first 10 years
after diagnosis-when they live up to a decade (48). This may
contribute to PD generally not being recognized as an illness
for which a palliative approach may be helpful (155, 156). A
US patient and caregivers council recommends palliative care to
be available from diagnosis of PD (138). This is also the ideal
of the European Parkinson’s Disease Association (EPDA) (157)
although they emphasize that when to start palliative care is an
individual decision.
Patients with dementia may have a number of needs in
the four domains of palliative care (physical, psychological,
social and spiritual) in addition to specific needs for a
peaceful, familiar environment, and practical support (104–106).
Typically, complex, multifaceted interventions could address
needs. Psychosocial needs may be pronounced in young-onset
dementia (onset under age 65) (158, 159). Patient advocacy
organizations recognize the importance of high-quality end-of-
life and palliative care in the advanced stages (132–134).
To measure symptom burden, specific tools are available
(Table 2, item e). For dementia, these typically involve proxy
(caregiver) report. Quality of care and dying assessment
tools specifically developed for dementia show the best
psychometric properties (129). For PD, there are adapted
versions of generic tools (118, 160). Regardless, effective use
of tools and implementation of complex interventions requires
multidisciplinary communication and team work (161).
Place of death varies by country (Table 2, item f). Patterns
are similar for dementia (120, 121) and PD (124), with dying
in nursing homes being common in many western countries
except Southern European countries with more frequent home
death, while hospital death is more common in Asian countries,
France and Hungary. In the UK, a trend of decreasing hospital
death and increasing nursing home death has been observed in
dementia (162). However, continuity of care may be problematic
across countries, with nursing home or hospital admissions
at the end of life in people with dementia and PD (122–
124, 163). Also, with PD, specific knowledge of the disease is
often suboptimal among nursing staff in nursing homes, while
upon admission, neurologists often stop seeing patients with PD,
with communication of neurologists with primary care being
suboptimal too (93, 94).
“Person-centered care, communication and shared decision
making” was among the most important domains of palliative
care in dementia according to experts around the world, and
it was prioritized for research (28). Advance care planning
(ACP) is a special form of ongoing communication about
preferred future health care (Table 2, items g and h). Researchers
and policy makers are increasingly interested in researching
and implementing ACP, and some beneficial effects have been
documented in dementia (23, 139, 140). However, there are
numerous barriers such as patient and family expecting the
physician to start it while physicians may not prioritize such
anticipatory care. Also, while many appreciate discussions, not
all would like to decide about future treatment (126, 164).
Similar barriers might exist in PD (141). In a synthesis of
studies, interview studies have shown physicians to be hesitant
in discussing progression of the disease in early disease stages as
they fear to diminish hope (17). Also patients indicate a conflicted
need as they reported both a wish for more information on
disease progression and death, and fear to receive the information
(“an information tension”) (17).
Family caregivers usually have information and support needs
in regards to proxy decision making and how to best care for
their loved one (28, 165) (Table 2, item i). They may experience
a magnitude of stress in caregiving and pre-grief in dementia
(145) and PD caregiving (150). In dementia, anticipatory grief
in response to compounded serial losses is common, and stress
in caregiving preceding physical death may be equal to or greater
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TABLE 2 | Conceptualization of the disease, needs of patients and family caregivers, and interventions.
Items about conceptualization,
needs and care
Dementia Parkinson’s disease
a. Treatment of the disease No curative treatment is available. Some drugs such as
Donepezil may improve cognition and behavior of people with
Alzheimer’s disease. It may not deserve labeling it as disease
modifying drugs; essentially this is palliative medication
because they do not slow the progression of, nor cure the
disease (100)
No curative or neuroprotective agents are available. A wide
range of treatment strategies are available for symptom
reduction, often requiring specific Parkinson’s disease
expertise. Available treatments are pharmacological (e.g.,
dopaminergic replacement), as well as rehabilitative (e.g.,
physiotherapy, occupational therapy) (101)
b. Conceptualization of the disease
as a terminal disease
Recognizing dementia as a terminal disease may help
providing adequate palliative care (28). However, about half of
family caregivers and nursing staff do not perceive it as a
terminal disease or a disease you can die from (102, 103)
To our best knowledge, there is no research that examines
perceptions about Parkinson’s disease as a terminal disease
c. Patient’s needs in an advanced
stage
In advanced dementia, needs may relate to the four domains
of palliative care (4), additionally, to (practical) support, and
important environmental needs such as a peaceful
environment (104–106). Familiarity of environment, routines
and people around who know the patient and can interpret
the behavior is also important (27, 107)
Prizer et al. (108) add financial needs to needs in the four
domains of palliative care and find that patients and families
report fewer needs in the financial and spiritual domains; on
average, as these needs are more variable between
individuals than needs in the other domains. Patients
preferred individualized care to address psychosocial issues,
adjustment to illness (particularly at diagnosis and with
progression), non-motor symptom control, and advance care
planning as an adjunct to usual care (109) and it is also
perceived as a social need (108). Patients and family
caregivers in Canada found that they are not receiving
enough information about diagnosis and prognosis (33)
d. Interventions to address needs in
particular in an advanced stage
Non-pharmacological treatment of symptoms such as
agitation is first choice (28, 100). Because symptoms are
easily missed and causes are not always easily identified,
systematic assessment and treatment (such as in the
stepwise STA OP! or STI intervention) is needed (110). Also
regular special programs (such as Namaste Care) (111) to
connect with people in the advanced stage in a peaceful
atmosphere are needed when they cannot participate
anymore in regular activities such as those offered in nursing
homes
Familiar rituals and music may be recognized until late
stages of the dementia and therefore it is important to know
religion or spiritual orientation (28, 59). Furthermore, spiritual,
and faith practice may help cope with the disease, to find
meaning in life, and they relate to wellbeing (59, 60)
Interventions are typically multifaceted and require specialist
knowledge, therefore intervention programs have focused on
enhancement of multidisciplinary collaboration and education
of professionals (e.g., the expert network of ParkinsonNet).
Evidence of effectiveness is becoming available, for
example occupation therapy, physiotherapy and integrated
multidisciplinary care (112–114). An international guideline in
palliative care for people with PD includes recommendations
for specific late-stage problems (115). However, no study has
focused specifically on addressing palliative care needs
e. Assessment tools Tools specific to dementia are needed for the assessment of
pain, distress and behavior (116, 117). There are over 30 pain
observation tools available (116) and there are also
inventories for multiple symptoms that, in contrast, include
pain as a single item such as the Integrated Palliative care
Outcome Scale for Dementia (117)
There are symptom assessment tools adapted from generic
tools that could identify specific palliative care needs in PD,
such as the Palliative care Outcome Scale Parkinson disease
(POS-PP) and the Edmonton Symptom Assessment System
Parkinson’s Disease (ESAS-PD) (49, 118, 119)
f. Place of death and continuity of
care
In western countries, people with dementia in a moderate or
severe stage are often admitted to a residential or nursing
home which is also the most common site of death in most
western countries. However, comparing several studies,
home death was more common in Southern European
countries and Mexico, and hospital death in (developed)
Asian countries (120). Japan, for example, refers patients with
dementia with behavioral problems to psychiatric inpatient
care and people may die there (121). Continuity of care in the
last year of life with dementia is problematic also in western
countries including in the US and Finland (122, 123)
A substantial proportion of deaths with PD occur in a hospital,
although there is wide variation between countries. A study in
11 countries showed that hospital death was most prevalent
in France, Hungary and South Korea, whereas nursing home
death was most common in New Zealand, Belgium, USA,
Canada and Czech Republic; and home death in Mexico,
Italy and Spain (124). Patients with PD had more physician
consultations and more emergency department visits per
year compared to patients without PD (125)
(Continued)
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TABLE 2 | Continued
Items about conceptualization,
needs and care
Dementia Parkinson’s disease
g. Communication, decision making
and the patient’s perspective
Due to increasing cognitive problems, communication with
people with dementia changes. Apprehension of risk changes
and health numeracy decreases; patients are often not
involved in treatment decisions (126, 127). Shared decision
making models need an extended preparatory phase to first
examine perceptions of the need for a decision (128)
Palliative care or comfort care is often, but not always
preferred for nursing home residents with dementia from the
perspective of patient and family caregiver, in different
countries (107, 129, 130). In a hypothetical situation of
advanced dementia, most older people would opt for comfort
care in a study in rural areas (131). Patient advocacy
organizations have issued recommendations for end-of-life
and palliative care in the advanced stages of dementia
(132–134)
Dissatisfactory communication with professionals is one of
the most common complaints of patients with PD (109, 135).
Treatment of the disease is mainly driven by the clinician (136)
In a hypothetical end-of-life situation the majority of proxies
of patients with advanced PD would choose comfort care as
the goal of treatment (137). A US patient and family caregiver
council advocates palliative care to be available from
diagnosis (138)
h. Advance care planning (ACP) ACP often does not start until the late stage when the patient
cannot be involved anymore. It is not always clear whose
responsibility it is, there are multiple barriers including patients
rather living by the day, and there may be discontinuity of
information with a change of setting of care (126). However, in
view of the cognitive decline, ACP is preferably started early
(28). There is also evidence of effectiveness to increase
advance decision making, family satisfaction with it, and other
outcomes (23, 139, 140)
Many patients want information on prognosis early in the
disease. Patients’ preferences regarding communication and
timing of end-of-life discussions vary (141). A full ACP
process may be perceived as lowering mood in an early stage
the disease, and should therefore be tailored to the stage of
the disease and individual preferences (135). Only a few
patients with PD who died in a UK hospital had had
end-of-life care discussions which were documented (142)
i. Care for families Family caregivers usually need support and care themselves
including support in proxy decision making, long before the
dying phase (28). Caring for a person with dementia is often
highly burdensome especially when behavioral symptoms
such as agitation and sleep disturbance develop (143). In
addition to higher caregiver burden, there are fewer positive
caregiving experiences, even at the end of life (144)
Pre-grief often occurs with the decline of the patient,
especially among spouses (145). Psychosocial interventions
may decrease pre-grief (146)
Family dynamic change (30, 68, 147–149), loss of autonomy,
economic strain and social isolation are part of the caregiver
burden
Pre-death grief was a significant finding in family caregivers
of patients with advanced PD and was associated with a
patient’s cognitive decline (150). In a review (151) of 30
studies about interventions to support caregivers only one
psychosocial intervention was shown to significantly decrease
psychosocial problems and need for help (152). Interventions
that embrace psycho-educational skills such as problem
solving, goal setting and cognitive restructuring can bring
benefit (29)
than stress in bereavement. Roland et al. (166) found caregiving
experiences and stressors to be similar between caregivers care
for a patient with dementia, PD, and PD and dementia.
Disease-Specific Palliative Care and
Practice
Disease-specific palliative care is needed; services and tools taken
uncritically from cancer palliative care have shown to not fit well
with dementia and require adaptation or even redevelopment
from scratch (27, 167, 168). Palliative care specialists, however,
may not know enough about the specifics of dementia and
PD. In addition to suboptimal access to palliative care (17)
access to disease-specific multidisciplinary care for PD may be
suboptimal (93, 169, 170).
Clearly, better integration of disease-specific and palliative
care expertise is needed. To establish dementia-specific palliative
care, the EAPC therefore recommends collaboration between
disease-specific (dementia) and palliative care (28). In the
UK there are initiatives for outreach with specialist dementia
palliative care to support the familiar care team (27, 171, 172).
Regarding PD, the provision of palliative care is widely
advocated (17, 29, 32, 173). A special task force of the
International Parkinson & Movement Disease Society is
dedicated to improving palliative care in PD (29, 174). A
mapping exercise in the UK showed service provision to vary
across regions, and services for PD were not well-integrated
with palliative care (175). There are some patchy examples of
integration of expertise from a palliative care department with
a neurology department (176). Patients and family caregivers
found they lacked knowledge about palliative care services.
Only few patients received care from a palliative care service
and coordination of care was poor (33, 147, 148). The need for
palliative care, including early in the disease trajectory, has been
emphasized by a collaborative statement from the EAPC and the
European Academy of Neurology (EAN) (177).
Among dementia care specialists, providing palliative care
early is controversial (154, 171). Soon after diagnosis, palliative
care can start in the form of ACP if patient and family caregiver
are willing to talk about the future (28). Waiting until an
advanced stage means many will never receive palliative care,
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mortality having been predicted inaccurately so patients die well
before palliative care issues could be addressed. Establishing
criteria to restrict access to US hospice care to those closest
to the end of life has been subject of considerable research
[e.g., (82, 85)]. Prediction research consistently shows we can
identify those likely to survive accurately, but not, or very few
of those likely to die. Needs may differ with more advanced
dementia though, and ideally, a needs-based approach is adopted
(176). Similarly, for people with PD, triggers for palliative care
(98) and access to US hospice care have been sought using a
mortality prediction approach (178). For example, a BMI less
than 18.5, accelerated weight loss and reduction of dopaminergic
medications was suggested for referral to US hospice care (178).
There is a lack of awareness about palliative care being
applicable to dementia both among the general public and
health care professionals, and this is perceived as a major
barrier to improve palliative care, for example by Dutch and
British physicians (179). Nursing staff may feel that they
lack competencies to deliver high-quality palliative dementia
care (Bolt et al., under review). Also, in PD, professionals
may feel uncertain about the palliative care they deliver and
often experience a lack of education and competence in this
field (155, 156, 180, 181).
CONCLUSION
Substantial research is being performed on dementia palliative
care. Much has happened since early descriptive research in
dementia compared symptoms and treatment with cancer [e.g.,
(182)], and introduced a hospice model of care (20). The research
has culminated into a clearer definition of what palliative care
should entail with dementia and into some understanding of
its effects. Comparisons with other diseases are now available
regarding a variety of aspects (e.g., a higher caregiver burden
compared with cancer (183), symptoms compared with various
other chronic-progressive diseases (184), or specific problems
described in subgroups with both dementia and cancer (185–
188). Nevertheless, it is still unclear what is important at what
stage and how to best incorporate individual preferences, for
example regarding discussions about future care.
PD follows an evenmore protracted course which complicates
a clear definition and there is no agreed-upon, evidence-based,
disease-specific conceptualization of palliative care. Even more
varied multidisciplinary expertise may be needed including also
dementia care expertise (in addition to PD disease-specific care,
palliative care and generic long-term care for older people).
More specific tools may also be needed, for example, application
of pain observation tools in PD dementia should consider
that facial expressions indicating pain are distinct [e.g., less
eye narrowing but similar upper lip raising (189)], to avoid
possible underreporting in Parkinson’s disease compared with
Alzheimer’s disease (190).
The combining of various expertise requires clear roles
and inter-professional collaboration which is challenging in
the face of uncertain disease trajectories (191). However,
integration of palliative care has shown to improve process
outcomes and patient and caregiver outcomes in cancer and
chronic-progressive disease (192). Integration should take
place at the clinical (patient) level but also, for example,
through relationships between professionals and between
organizations and in the wider system (193). For this,
multidisciplinary networking and teams sharing expertise
BOX 1 | Basic recommendations for practice of palliative care based on similarities and divergences between progressive neurological diseases and available
evidence∗.
1) Do not wait with bringing palliative care to the table until a late or terminal stage of the disease. Although it seems an obvious and safe choice to limit to a late
stage, it may be too late to involve the patient or to implement a palliative care treatment plan. With PD, there is often opportunity to speak about palliative care
when cognitive problems are still mild or absent. With dementia, it is difficult to predict who will die already before the late stage, while many will, with unmet
palliative care needs. Therefore, discussion of palliative care before a moderate stage is recommended.
2) Improving awareness, among all involved, of the progressive course of the disease supports a shared understanding of the disease, implications for death and
dying and what it means for the individuals involved. This will be helpful in identifying and addressing palliative care needs.
3) Common causes of hospital admissions include pneumonia, sepsis, and falls. Physicians could discuss these scenarios as a starting point to establish patients’
views and preferences regarding invasive therapies and the benefits of a palliative care approach.
4) Elicit preferences of patient and family and the preferred style with regard to talking about future care and end-of-life scenarios. Address any information needs,
and a step-wise approach with discussions continued later on may avoid feelings of being overwhelmed.
5) The course of the disease is uncertain, whereas change is. All members of a care team should help identify and discuss subtle changes in symptom and caregiver
burden early.
6) Palliative care is an approach in which intervening is still possible even if active treatment of the disease or its complications is not possible or when other treatment
is being withheld. It can be a potent adjunct to usual care but it should be well-integrated, also at a system level. As opposed to being uniform, straightforward,
hassle free fix, “multi” is the important term in this: multifaceted interventions targeted to the individual in a context of multidisciplinary collaboration between
generalists and disease and palliative care specialists.
7) Tools to identify needs and a change in the patient’s condition (physical, psychosocial, spiritual, caregiver needs) should be sufficiently specific to the disease
while a context or setting specific system should be in place to support its continued use (for example, a systematic approach to managing pain, behavioral
symptoms, autonomic dysfunction, sleep dysfunction or motor fluctuations/dyskinesias sustainably implemented in long-term or acute care).
8) Pre-grief with progressive decline of the patient and prolonged social isolation are common. Psychosocial support is needed in different phases to empower
patients and family caregivers to cope with both chronic stressors and crises.
∗We inferred this general and more disease-specific guidance from the items on course of the diseases and conceptualizations in Tables 1, 2, acknowledging that
these are only a couple of key recommendations and that evidence is limited. Also, this guidance should be refined and fit the local context when implemented. For
more detailed guidance for clinical practice, we refer to the recommendations as part of the European Association for Palliative Care (EAPC) dementia white paper
(28) and guidelines from the Irish Palliative Care in Parkinson’s Disease Group (115).
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is important, supported more formally by shared guidelines and
pathways (194).
Sawatzky et al. (18) describe three reasons how a clear
conceptualization of palliative care in chronic-progressive disease
may be helpful: (1) earlier recognition (“upstream”) of needs, (2)
to promote adaptation of palliative care knowledge and expertise
for unique disease profiles, (3) to operationalize a palliative
approach through integration into systems and models of care
that do not specialize in palliative care. Such conceptualization
is promoted by looking at similarities with other diseases with
more established palliative care models, but also taking a closer
look at divergences, such as the initial stable phase in PD
and how this should affect palliative care services. It raises the
question whether ACP is an integral part of palliative care, or
could precede it, also for dementia considering ambiguity around
early palliative care. This resonates with recommendations of
Temel et al. (195) for “early” palliative care to depend on
the type of cancer; with low symptom burden, waiting until a
change in health status or emergency room admission may be a
reasonable approach.
For palliative dementia care, it has been helpful to also
consider how it differs from “usual” dementia care, for example,
by a highly proactive approach. Such understanding of what
needs to be changed in practice facilitates the integration of
a palliative approach in dementia care so that ultimately, the
integrated care becomes the standard (196). With Kluger et al.
(29), we believe that palliative care in PD will benefit from a
clearer conceptualization.
Although probably not directly suitable as entry criteria
for palliative care, research on prognostic factors in PD may
be helpful. For example, ADL dependency strongly predicts
mortality in older people and in dementia (80, 81, 85), probably
covering cognitive and physical impairments and other risk
factors. In contrast, it may not predict mortality in PD well
(98), perhaps because motor function declines early; some
dependency therefore occurs earlier than in dementia. Further,
we agree that more work is needed regarding assessment of
needs–including spiritual needs, development of assessment and
educational tools and interventions for patient and caregiver
support (29, 108).
Although we could not compare directly, we hope that our
review contributes to an emerging understanding as to what
elements of palliative care with neurological conditions are
disease-specific and which are more general. We acknowledge
that the brevity of the review did not allow more depth regarding
aspects of the disease and care in different types of the diseases or
forms of parkinsonism which need further research. More could
be written about possible implications such as how to organize
disease-specific palliative care in a cost-effective manner. We
recognize a need for basic guidance for clinical practice which
we offer in Box 1, awaiting high-quality trials and other research
we need to build refined evidence-based practices that optimally
serve individuals with neurological disease.
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